ERBB2 and breast cancer: Figure 3 shows that the BOADICEA, BRCAPRO, Myriad, and Penn II models had better predictive accuracies in the triple negative breast cancer group (Fig. 3a, AUC 0.78, 0.80, 0.75, and 0.74, respectively) than in the luminal or HER2-overexpressed breast cancer group (Fig. 3b, AUC 0.69, 0.65, 0.65, and 0.63, respectively).